Clik here to view.
Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and...
View ArticleClik here to view.
拓臻生物将在2019美国肝病研究协会年会上发表FXR激动剂TERN-101临床前研究数据
美国加州福斯特城与中国上海 (美国商业资讯)–Terns Pharmaceuticals...
View ArticleClik here to view.
Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist...
FOSTER CITY, Calif. & SHANGHAI Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis...
View ArticleClik here to view.
C-Path, CDISC Develop Standard to Represent Data for Animal Rule Studies
TUCSON, Ariz. & AUSTIN, Texas The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the...
View ArticleClik here to view.
Sun Pharma Launches Drizalma Sprinkle in the U.S.
MUMBAI, India & PRINCETON, N.J. Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” including its subsidiaries and/or associate...
View ArticleClik here to view.
HitGen Enters into DNA-Encoded Library Based Drug Discovery Research...
CHENGDU, China HitGen Inc. today announced that it has entered into a drug discovery research collaboration with Galapagos NV to identify potential small molecule leads against targets of interest...
View ArticleClik here to view.
Terns Pharmaceuticalsが2019年米国肝臓学会議でFXR作動薬TERN-101の良好な前臨床データを発表へ
米カリフォルニア州フォスターシティ & 上海 （ビジネスワイヤ） — 非アルコール性脂肪肝炎（NASH）とがんの革新的治療薬の創薬と開発に傾注する世界的バイオ製薬会社のTerns Pharmaceuticals,...
View ArticleClik here to view.
Vaxess and GC Pharma to Collaborate on Development of Highly Effective...
CAMBRIDGE, Mass. & SEOUL, South Korea GC Pharma, a leading manufacturer of influenza vaccines with a global reach, and Vaxess, an innovative biotechnology company developing the MIMIX smart...
View ArticleClik here to view.
LPIXEL Announces Approval and Launch of Japan’s First Deep Learning-Powered...
TOKYO LPIXEL Inc., a leader in image analysis and processing in life science and medical research, announced today the approval of “EIRL aneurysm,” its image analysis software that uses deep...
View ArticleClik here to view.
U.S. FDA Advisory Committee Recommends Approval of Cefiderocol for Treatment...
OSAKA, Japan & FLORHAM PARK, N.J. Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee voted...
View ArticleClik here to view.
More People in Phnom Penh Living With Kidney Disease Will Have Access to...
PHNOM PENH, Cambodia Fresenius Medical Care, the world’s leading provider of dialysis products and services, has collaborated with Hebron Medical Center (HMC) to bring high-quality, affordable...
View ArticleClik here to view.
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted...
View ArticleClik here to view.
NeuClone Announces First Human Dose of Stelara® (Ustekinumab) Biosimilar...
SYDNEY NeuClone, a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it has commenced dosing of Stelara® (ustekinumab)...
View ArticleClik here to view.
The Lancet Respiratory Medicine Published Study Shows Ensartinib Holds...
PALM BEACH GARDENS, Fla. Xcovery Holdings, Inc., an oncology-focused biopharmaceutical company, today announced that ensartinib, the company’s lead drug candidate, demonstrated efficacy and safety...
View ArticleClik here to view.
Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO®...
LONDON Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12...
View ArticleClik here to view.
Retrospective Real-World Comparative Analysis Highlights Safety of...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from a retrospective chart review study (EVOLVE), which investigated the likelihood of...
View ArticleClik here to view.
Solasia Announces Approval of episil® oral liquid in South Korea
TOKYO Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today officially...
View ArticleClik here to view.
ResMed Introduces AirFit N30, World’s First Tube-Down Nasal Cradle CPAP Mask
SAN DIEGO ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit N30, the world’s first tube-down nasal cradle CPAP mask with a front-facing tube – a brand-new option for sleep apnea treatment. This...
View ArticleClik here to view.
Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR...
OSAKA, Japan & CHICAGO Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”) today announced that Takeda has acquired an...
View ArticleClik here to view.
瑞思迈推出世界首款通气管下弯型鼻垫CPAP面罩AirFit N30
圣迭戈 (美国商业资讯)–瑞思迈(ResMed)(NYSE: RMD)(ASX: RMD)今天推出世界首款配置前置式通气管的通气管下弯型鼻垫CPAP面罩AirFit N30——用于治疗睡眠呼吸暂停的全新选择。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20191022005503/zh-CN/ ResMed...
View Article